Gender Issues in Venous Thromboembolism

Susan Murin, Kathryn Bilello, Lisa Moores, Aaron Holley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Venous thromboembolism (VTE) causes substantial morbidity and mortality. The incidence of VTE does not appear to vary significantly by gender, as evidenced by a lack of consistency in the magnitude and even direction of effect of gender in a variety of epidemiological studies of varying design. Gender does appear to affect VTE recurrence, with men having a higher rate of recurrent VTE than women. The main influence of gender upon VTE is the relationship between female gender and several well-recognized clinical risk factors for VTE: oral contraceptive pill (OCP) use, hormone replacement therapy, estrogen receptor modulator therapy, and pregnancy. The fact that women of childbearing age do not appear to have a substantially greater incidence of VTE compared to age-matched men may reflect an offsetting of these female-specific risk factors by other risk factors that are more common in men, such as trauma. Hormonal therapies are associated with a two- to three-fold increase in VTE incidence. Risk is higher with some formulations than others, during initial use, and among women who are obese, smoke, or have one of several forms of heritable thrombophilia. The pregnant state is associated with a three- to five-fold increase in VTE risk, and thromboembolism is a major cause of peripartum death. Heritable forms of thrombophilia are also important co-determinants of VTE risk in pregnancy. The mechanisms through which pregnancy and hormonal therapies increase VTE risk have not been definitively established, but hormonal effects upon levels of coagulation and anticoagulation factors likely play a role. Venous compression and venous injury also contribute to increased risk in the pregnant state.

Original languageEnglish (US)
Title of host publicationPrinciples of Gender-Specific Medicine
PublisherElsevier Inc.
Pages225-243
Number of pages19
ISBN (Print)9780123742711
DOIs
StatePublished - 2010

Fingerprint

Venous Thromboembolism
Interpersonal Relations
Thrombophilia
Pregnancy
Incidence
Peripartum Period
Estrogen Receptor Modulators
Blood Coagulation Factors
Thromboembolism
Hormone Replacement Therapy
Wounds and Injuries
Oral Contraceptives
Smoke
Epidemiologic Studies
Cause of Death
Therapeutics
Morbidity
Recurrence

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Murin, S., Bilello, K., Moores, L., & Holley, A. (2010). Gender Issues in Venous Thromboembolism. In Principles of Gender-Specific Medicine (pp. 225-243). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374271-1.00020-4

Gender Issues in Venous Thromboembolism. / Murin, Susan; Bilello, Kathryn; Moores, Lisa; Holley, Aaron.

Principles of Gender-Specific Medicine. Elsevier Inc., 2010. p. 225-243.

Research output: Chapter in Book/Report/Conference proceedingChapter

Murin, S, Bilello, K, Moores, L & Holley, A 2010, Gender Issues in Venous Thromboembolism. in Principles of Gender-Specific Medicine. Elsevier Inc., pp. 225-243. https://doi.org/10.1016/B978-0-12-374271-1.00020-4
Murin S, Bilello K, Moores L, Holley A. Gender Issues in Venous Thromboembolism. In Principles of Gender-Specific Medicine. Elsevier Inc. 2010. p. 225-243 https://doi.org/10.1016/B978-0-12-374271-1.00020-4
Murin, Susan ; Bilello, Kathryn ; Moores, Lisa ; Holley, Aaron. / Gender Issues in Venous Thromboembolism. Principles of Gender-Specific Medicine. Elsevier Inc., 2010. pp. 225-243
@inbook{9dac2d66ab874ebea86a19639a1546b1,
title = "Gender Issues in Venous Thromboembolism",
abstract = "Venous thromboembolism (VTE) causes substantial morbidity and mortality. The incidence of VTE does not appear to vary significantly by gender, as evidenced by a lack of consistency in the magnitude and even direction of effect of gender in a variety of epidemiological studies of varying design. Gender does appear to affect VTE recurrence, with men having a higher rate of recurrent VTE than women. The main influence of gender upon VTE is the relationship between female gender and several well-recognized clinical risk factors for VTE: oral contraceptive pill (OCP) use, hormone replacement therapy, estrogen receptor modulator therapy, and pregnancy. The fact that women of childbearing age do not appear to have a substantially greater incidence of VTE compared to age-matched men may reflect an offsetting of these female-specific risk factors by other risk factors that are more common in men, such as trauma. Hormonal therapies are associated with a two- to three-fold increase in VTE incidence. Risk is higher with some formulations than others, during initial use, and among women who are obese, smoke, or have one of several forms of heritable thrombophilia. The pregnant state is associated with a three- to five-fold increase in VTE risk, and thromboembolism is a major cause of peripartum death. Heritable forms of thrombophilia are also important co-determinants of VTE risk in pregnancy. The mechanisms through which pregnancy and hormonal therapies increase VTE risk have not been definitively established, but hormonal effects upon levels of coagulation and anticoagulation factors likely play a role. Venous compression and venous injury also contribute to increased risk in the pregnant state.",
author = "Susan Murin and Kathryn Bilello and Lisa Moores and Aaron Holley",
year = "2010",
doi = "10.1016/B978-0-12-374271-1.00020-4",
language = "English (US)",
isbn = "9780123742711",
pages = "225--243",
booktitle = "Principles of Gender-Specific Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Gender Issues in Venous Thromboembolism

AU - Murin, Susan

AU - Bilello, Kathryn

AU - Moores, Lisa

AU - Holley, Aaron

PY - 2010

Y1 - 2010

N2 - Venous thromboembolism (VTE) causes substantial morbidity and mortality. The incidence of VTE does not appear to vary significantly by gender, as evidenced by a lack of consistency in the magnitude and even direction of effect of gender in a variety of epidemiological studies of varying design. Gender does appear to affect VTE recurrence, with men having a higher rate of recurrent VTE than women. The main influence of gender upon VTE is the relationship between female gender and several well-recognized clinical risk factors for VTE: oral contraceptive pill (OCP) use, hormone replacement therapy, estrogen receptor modulator therapy, and pregnancy. The fact that women of childbearing age do not appear to have a substantially greater incidence of VTE compared to age-matched men may reflect an offsetting of these female-specific risk factors by other risk factors that are more common in men, such as trauma. Hormonal therapies are associated with a two- to three-fold increase in VTE incidence. Risk is higher with some formulations than others, during initial use, and among women who are obese, smoke, or have one of several forms of heritable thrombophilia. The pregnant state is associated with a three- to five-fold increase in VTE risk, and thromboembolism is a major cause of peripartum death. Heritable forms of thrombophilia are also important co-determinants of VTE risk in pregnancy. The mechanisms through which pregnancy and hormonal therapies increase VTE risk have not been definitively established, but hormonal effects upon levels of coagulation and anticoagulation factors likely play a role. Venous compression and venous injury also contribute to increased risk in the pregnant state.

AB - Venous thromboembolism (VTE) causes substantial morbidity and mortality. The incidence of VTE does not appear to vary significantly by gender, as evidenced by a lack of consistency in the magnitude and even direction of effect of gender in a variety of epidemiological studies of varying design. Gender does appear to affect VTE recurrence, with men having a higher rate of recurrent VTE than women. The main influence of gender upon VTE is the relationship between female gender and several well-recognized clinical risk factors for VTE: oral contraceptive pill (OCP) use, hormone replacement therapy, estrogen receptor modulator therapy, and pregnancy. The fact that women of childbearing age do not appear to have a substantially greater incidence of VTE compared to age-matched men may reflect an offsetting of these female-specific risk factors by other risk factors that are more common in men, such as trauma. Hormonal therapies are associated with a two- to three-fold increase in VTE incidence. Risk is higher with some formulations than others, during initial use, and among women who are obese, smoke, or have one of several forms of heritable thrombophilia. The pregnant state is associated with a three- to five-fold increase in VTE risk, and thromboembolism is a major cause of peripartum death. Heritable forms of thrombophilia are also important co-determinants of VTE risk in pregnancy. The mechanisms through which pregnancy and hormonal therapies increase VTE risk have not been definitively established, but hormonal effects upon levels of coagulation and anticoagulation factors likely play a role. Venous compression and venous injury also contribute to increased risk in the pregnant state.

UR - http://www.scopus.com/inward/record.url?scp=84882543505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882543505&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374271-1.00020-4

DO - 10.1016/B978-0-12-374271-1.00020-4

M3 - Chapter

AN - SCOPUS:84882543505

SN - 9780123742711

SP - 225

EP - 243

BT - Principles of Gender-Specific Medicine

PB - Elsevier Inc.

ER -